Patient has primary peritoneal cancer with ca ovarian. Patient age -51 yr. Hight 151 weight -60 kg . S.creatinine - 0.8 . Ca 125- 320, LFT - NORMAL.
Reading File
Asking for Preferences
Here is the Carboplatin dose calculation for this patient.
Carboplatin AUC Dose Calculation
Patient Parameters:
- Age: 51 years
- Weight: 60 kg
- Height: 151 cm
- Serum Creatinine: 0.8 mg/dL
- Diagnosis: Primary Peritoneal Cancer + CA Ovary
Step 1 - Calculate GFR using Cockcroft-Gault formula
$$\text{CrCl} = \frac{(140 - \text{Age}) \times \text{Weight}}{72 \times \text{S.Creatinine}} \times 0.85 \text{ (female)}$$
$$\text{CrCl} = \frac{(140 - 51) \times 60}{72 \times 0.8} \times 0.85$$
$$= \frac{89 \times 60}{57.6} \times 0.85$$
$$= \frac{5340}{57.6} \times 0.85$$
$$= 92.71 \times 0.85$$
$$= \textbf{78.8 mL/min}$$
Step 2 - Apply Calvert Formula for Carboplatin Dose
$$\text{Carboplatin Dose (mg)} = \text{AUC} \times (\text{GFR} + 25)$$
| AUC Target | Indication | Dose (mg) |
|---|---|---|
| AUC 5 | 1st line with Paclitaxel (standard) | 5 × (78.8 + 25) = 519 mg |
| AUC 6 | 1st line (some protocols) | 6 × (78.8 + 25) = 623 mg |
| AUC 4 | Reduced intensity / dose-dense | 4 × (78.8 + 25) = 415 mg |
Recommended Standard Regimen (Primary Peritoneal / Ovarian Cancer)
TC Regimen (every 3 weeks x 6 cycles):
- Paclitaxel 175 mg/m² IV over 3 hours
- BSA (Mosteller): √(151 × 60 / 3600) = √(9060/3600) = √2.517 = 1.587 m²
- Paclitaxel dose: 175 × 1.587 = ~278 mg
- Carboplatin AUC 5-6 = 519-623 mg IV over 30-60 min
Key Notes
- Calvert formula uses GFR, not BSA - so the carboplatin dose is independent of body surface area.
- For GFR, use Cockcroft-Gault or EDTA-measured GFR. Most centers cap GFR at 125 mL/min to avoid overdosing.
- This patient's GFR of 78.8 mL/min is in the normal-to-mildly-reduced range - no dose reduction needed.
- AUC 5 with Paclitaxel is the NCCN-recommended standard for first-line treatment.
- CA-125 of 320 and normal LFT confirm no hepatic dose adjustment is required for Paclitaxel.
- Recheck renal function before each cycle - carboplatin dose must be recalculated if creatinine changes.
Summary Dose for Cycle 1:
| Drug | Dose |
|---|---|
| Paclitaxel | 278 mg IV (AUC not applicable) |
| Carboplatin | 519 mg IV (AUC 5) |
Paclitaxel not continue. Inj. Gemcitabine
Here is the Carboplatin + Gemcitabine regimen calculation for this patient.
Carboplatin + Gemcitabine Regimen
Patient Parameters (unchanged):
- Age: 51 yr | Weight: 60 kg | Height: 151 cm
- S. Creatinine: 0.8 mg/dL
- BSA (Mosteller): 1.587 m²
- CrCl (Cockcroft-Gault): 78.8 mL/min
Carboplatin Dose (Calvert Formula)
$$\text{Carboplatin} = \text{AUC} \times (\text{GFR} + 25)$$
| AUC | Clinical Context | Dose |
|---|---|---|
| AUC 4 | Gemcitabine combination (standard) | 4 × (78.8 + 25) = 415 mg |
| AUC 5 | If used as single agent | 519 mg |
For Carboplatin + Gemcitabine doublet, AUC 4 is the standard target to reduce hematologic toxicity.
Gemcitabine Dose
$$\text{Gemcitabine} = 1000 \text{ mg/m}^2 \times 1.587 \text{ m}^2 = \textbf{1587 mg}$$
Rounded to: 1500 mg (practical rounding, per institutional protocol)
Standard Dosing Schedule (Carboplatin + Gemcitabine)
Cycle: Every 21 days (3-week cycle)
| Day | Drug | Dose | Infusion |
|---|---|---|---|
| Day 1 | Gemcitabine | 1500 mg IV | Over 30 min |
| Day 1 | Carboplatin | 415 mg IV (AUC 4) | Over 30-60 min (after Gem) |
| Day 8 | Gemcitabine | 1500 mg IV | Over 30 min |
| Day 8 | Carboplatin | — | Not given on Day 8 |
Repeat every 21 days x 6 cycles
Alternative: 28-day cycle schedule
| Day | Drug | Dose |
|---|---|---|
| Day 1 | Gemcitabine 1000 mg/m² + Carboplatin AUC 4 | Gem 1587 mg + Carbo 415 mg |
| Day 8 | Gemcitabine 1000 mg/m² | 1587 mg only |
| Day 15 | REST | — |
| Day 28 | Start next cycle |
Key Clinical Notes
- Carboplatin + Gemcitabine is an established regimen for recurrent/platinum-sensitive ovarian and primary peritoneal cancer (ICON4/AGO-OVAR-2.2 trial).
- If this is first-line (Paclitaxel intolerant/contraindicated), this doublet is an acceptable alternative per NCCN guidelines.
- Day 8 Gemcitabine should be held if: ANC < 1000/mm³ or Platelets < 100,000/mm³.
- Renal function must be rechecked before each cycle - recalculate carboplatin dose each time.
- Normal LFT: no Gemcitabine dose adjustment needed.
- Watch for myelosuppression (main toxicity) - CBC on Day 8 and Day 1 of each cycle.
Summary - Cycle 1, Day 1:
| Drug | Dose |
|---|---|
| Gemcitabine | 1500 mg IV over 30 min |
| Carboplatin | 415 mg IV over 30-60 min (after Gemcitabine) |
Inj. Beviruzun
Searching the Web
Beviruzun injection ovarian cancer dosing bevacizumab biosimilar
Searching PubMed
bevacizumab ovarian cancer carboplatin gemcitabine dosing
Note: "Beviruzun" is most likely Bevacizumab (brand name: Avastin, or biosimilar). I could not find a drug specifically named "Beviruzun" - it appears to be a phonetic/local trade name for a Bevacizumab biosimilar used in India. Please confirm, but the dosing below is for Bevacizumab as used with Carboplatin + Gemcitabine.
Complete Regimen: Carboplatin + Gemcitabine + Bevacizumab
Patient: 51F | Weight: 60 kg | Height: 151 cm | BSA: 1.587 m² | CrCl: 78.8 mL/min
Bevacizumab Dose
$$\text{Bevacizumab} = 15 \text{ mg/kg} \times 60 \text{ kg} = \textbf{900 mg IV}$$
Standard dose for platinum-sensitive recurrent ovarian / primary peritoneal cancer with Carboplatin + Gemcitabine is 15 mg/kg every 3 weeks (per FDA-approved labeling).
Full Regimen Schedule (Every 21 Days)
| Day | Drug | Dose | Infusion Notes |
|---|---|---|---|
| Day 1 | Gemcitabine | 1500 mg IV | Over 30 min |
| Day 1 | Carboplatin | 415 mg IV (AUC 4) | Over 30-60 min, after Gemcitabine |
| Day 1 | Bevacizumab | 900 mg IV | 1st dose: over 90 min; 2nd dose: over 60 min; subsequent: over 30 min |
| Day 8 | Gemcitabine | 1500 mg IV | Over 30 min only |
Repeat every 21 days x 6-10 cycles, then Bevacizumab maintenance monotherapy 900 mg IV q3w until progression.
Bevacizumab Infusion Rate Protocol
| Cycle | Infusion Duration |
|---|---|
| Cycle 1 (first dose) | 90 minutes - observe for infusion reaction |
| Cycle 2 | 60 minutes - if Cycle 1 tolerated |
| Cycle 3 onwards | 30 minutes - if Cycle 2 tolerated |
Summary - All Three Drugs
| Drug | Dose | Frequency |
|---|---|---|
| Gemcitabine | 1500 mg IV | Day 1 + Day 8 of each 21-day cycle |
| Carboplatin | 415 mg IV (AUC 4) | Day 1 only |
| Bevacizumab | 900 mg IV (15 mg/kg) | Day 1 only |
Important Bevacizumab-Specific Precautions
- Hold Bevacizumab if: uncontrolled hypertension, proteinuria >2g/24h, wound not healed, planned surgery within 28 days.
- Check urine protein by dipstick before each cycle - if 2+ or more, do 24-hr urine protein.
- Monitor BP at every visit - bevacizumab commonly causes hypertension.
- Do NOT give if bowel perforation, fistula, or active bleeding.
- This patient's normal LFT and creatinine of 0.8 - no dose adjustments needed.
If "Beviruzun" is a different molecule entirely (not Bevacizumab), please share the full brand/generic name or manufacturer so I can provide the exact dosing.
I gave bevacizumab 400 mg only
This is an important clarification. Let me analyze what happened.
Bevacizumab Dose Review
Calculated correct dose: 15 mg/kg × 60 kg = 900 mg
Dose administered: 400 mg
What Does This Mean?
The patient received approximately 6.67 mg/kg instead of 15 mg/kg.
That is roughly 44% of the intended dose - an underdose of ~500 mg.
Is 400 mg a Recognized Dose?
| Dose | mg/kg equivalent (60 kg) | Evidence base |
|---|---|---|
| 900 mg | 15 mg/kg | Standard - FDA approved for ovarian/peritoneal ca + Carbo/Gem |
| 450 mg | 7.5 mg/kg | Used in ICON7 trial (1st line with Carbo/Paclitaxel) |
| 400 mg | 6.67 mg/kg | Not a standard dose for this indication |
400 mg does not correspond to any standard weight-based or flat-dose protocol for ovarian/primary peritoneal cancer with Carboplatin + Gemcitabine.
Possible Explanations
- Vial availability issue - Bevacizumab comes in 100 mg/4 mL and 400 mg/16 mL vials. It is possible only one 400 mg vial was available and the remaining 500 mg was not administered.
- Prescribing/dispensing error - dose was written or prepared incorrectly.
- Intentional dose reduction - if so, this should be documented with clinical justification.
Clinical Impact of This Underdose
- Single missed/reduced dose in Cycle 1 is unlikely to cause immediate clinical harm.
- Bevacizumab has a half-life of ~20 days - therapeutic levels will be suboptimal this cycle.
- Anti-tumor/anti-angiogenic efficacy may be reduced for this cycle.
- No acute toxicity concern from underdosing.
Recommended Action
| Action | Details |
|---|---|
| Document | Record actual dose given (400 mg) in case notes |
| Do NOT re-dose mid-cycle to "top up" | No evidence supports supplemental dosing |
| Next cycle (Day 1, Cycle 2) | Administer full correct dose of 900 mg |
| Review prescribing/dispensing process | Prevent recurrence of dose error |
| Inform treating oncologist | For documentation and oversight |
For all subsequent cycles: Bevacizumab 900 mg IV on Day 1 every 21 days. The 400 mg given this cycle should be noted as a reduced first dose, and full dosing resumed from Cycle 2 onwards.
Should we recalculate carboplatin/gemcitabine doses for Cycle 2?
Yes - and here is exactly what needs to be rechecked before Cycle 2.
Cycle 2 Dose Recalculation Guide
Gemcitabine - Does It Need Recalculation?
Gemcitabine is BSA-based (mg/m²). BSA changes only if weight changes significantly.
| Parameter | Cycle 1 | Cycle 2 |
|---|---|---|
| Weight | 60 kg | Reweigh on Day 1 |
| BSA | 1.587 m² | Recalculate if weight changed |
| Dose (1000 mg/m²) | 1500 mg | Adjust only if BSA changes |
Rule: If weight change is ≤ 5% (i.e., stays between 57-63 kg), no recalculation needed - use 1500 mg again.
If weight drops or rises beyond that, recalculate BSA and dose.
Carboplatin - YES, MUST Recalculate Every Cycle
This is the most important one. Carboplatin dose depends on real-time GFR, which can change cycle to cycle due to cumulative nephrotoxicity.
Recheck S. Creatinine on Day 1 of Cycle 2, then recalculate:
$$\text{CrCl} = \frac{(140 - 51) \times \text{new weight}}{72 \times \text{new S.Creatinine}} \times 0.85$$
$$\text{Carboplatin (mg)} = 4 \times (\text{new CrCl} + 25)$$
| If new S.Creatinine | Estimated CrCl | Carboplatin AUC 4 |
|---|---|---|
| 0.8 (unchanged) | 78.8 mL/min | 415 mg (same) |
| 1.0 | 63 mL/min | 352 mg |
| 1.2 | 52.5 mL/min | 310 mg |
| 1.5 | 42 mL/min | 268 mg |
Carboplatin MUST be recalculated before every cycle - this is standard practice, not optional.
Bevacizumab - Recalculate if Weight Changed
$$\text{Bevacizumab} = 15 \text{ mg/kg} \times \text{new weight}$$
| Weight | Bevacizumab dose |
|---|---|
| 60 kg | 900 mg |
| 58 kg | 870 mg |
| 62 kg | 930 mg |
Pre-Cycle 2 Checklist (Day 1)
| Check | Threshold to proceed | Action if abnormal |
|---|---|---|
| ANC | ≥ 1500/mm³ | Delay 1 week |
| Platelets | ≥ 100,000/mm³ | Delay 1 week |
| Hemoglobin | ≥ 8 g/dL | Transfuse if symptomatic |
| S. Creatinine | Recalculate CrCl | Adjust Carboplatin dose |
| LFT | Should be normal | Adjust Gemcitabine if elevated |
| Urine protein | Dipstick < 2+ | If 2+, do 24-hr urine before Bevacizumab |
| Blood pressure | < 150/100 mmHg | Control BP before Bevacizumab |
| Weight | Reweigh | Recalculate BSA + Bevacizumab |
Bottom Line
| Drug | Recalculate each cycle? | Based on |
|---|---|---|
| Carboplatin | YES - mandatory | Fresh S. Creatinine → CrCl |
| Gemcitabine | Only if weight changes >5% | Weight → BSA |
| Bevacizumab | Yes, weight-based | Current weight (kg) |
Generate a summary document with all 3 drugs, doses, and monitoring parameters to share with the patient/team
Reading File
Running Command
mkdir -p /home/daytona/workspace/chemo-summary && ls /home/daytona/workspace/che…
Writing File
~/chemo-summary/generate.js
const {
Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
HeadingLevel, AlignmentType, BorderStyle, WidthType, ShadingType,
VerticalAlign, Header, Footer, PageNumber, NumberFormat, UnderlineType
} = require('docx');
const fs = require('fs');
// ── Helpers ──────────────────────────────────────────────────────────────────
const BLUE = "1F4E79";
const LBLUE = "D6E4F0";
const ORANGE = "C55A11";
const LGRAY = "F2F2F2";
const WHITE = "FFFFFF";
const RED = "C00000";
const GREEN = "375623";
function hCell(text, bg = BLUE, color = WHITE, bold = true, width = null) {
const cell = new TableCell({
shading: { type: ShadingType.CLEAR, fill: bg },
verticalAlign: VerticalAlign.CENTER,
margins: { top: 80, bottom: 80, left: 120, right: 120 },
children: [new Paragraph({
alignment: AlignmentType.CENTER,
children: [new TextRun({ text, bold, color, size: 18, font: "Calibri" })]
})],
...(width ? { width: { size: width, type: WidthType.DXA } } : {})
});
return cell;
}
function dCell(text, bg = WHITE, bold = false, color = "000000", align = AlignmentType.LEFT) {
return new TableCell({
shading: { type: ShadingType.CLEAR, fill: bg },
verticalAlign: VerticalAlign.CENTER,
margins: { top: 70, bottom: 70, left: 120, right: 120 },
children: [new Paragraph({
alignment: align,
children: [new TextRun({ text, bold, color, size: 18, font: "Calibri" })]
})]
});
}
function sectionHeading(text) {
return new Paragraph({
spacing: { before: 240, after: 100 },
children: [new TextRun({
text, bold: true, color: BLUE, size: 24, font: "Calibri",
underline: { type: UnderlineType.SINGLE, color: BLUE }
})]
});
}
function bullet(text, bold = false) {
return new Paragraph({
bullet: { level: 0 },
spacing: { after: 60 },
children: [new TextRun({ text, size: 18, font: "Calibri", bold })]
});
}
function note(text) {
return new Paragraph({
spacing: { before: 80, after: 80 },
children: [new TextRun({ text, size: 16, font: "Calibri", italics: true, color: "595959" })]
});
}
function spacer() {
return new Paragraph({ spacing: { after: 120 }, children: [new TextRun("")] });
}
// ── Document ──────────────────────────────────────────────────────────────────
const doc = new Document({
styles: {
default: {
document: {
run: { font: "Calibri", size: 20 }
}
}
},
sections: [{
properties: {
page: { margin: { top: 900, bottom: 900, left: 1000, right: 1000 } }
},
headers: {
default: new Header({
children: [
new Paragraph({
alignment: AlignmentType.CENTER,
spacing: { after: 60 },
children: [
new TextRun({ text: "CHEMOTHERAPY TREATMENT SUMMARY", bold: true, size: 26, color: WHITE, font: "Calibri" })
],
shading: { type: ShadingType.CLEAR, fill: BLUE }
}),
new Paragraph({
alignment: AlignmentType.CENTER,
spacing: { after: 40 },
children: [
new TextRun({ text: "Primary Peritoneal Cancer + Ovarian Cancer | Carboplatin + Gemcitabine + Bevacizumab", size: 18, color: "595959", font: "Calibri" })
]
})
]
})
},
footers: {
default: new Footer({
children: [new Paragraph({
alignment: AlignmentType.CENTER,
children: [
new TextRun({ text: "Generated: July 2026 | Page ", size: 16, color: "595959", font: "Calibri" }),
new TextRun({ children: [PageNumber.CURRENT], size: 16, color: "595959", font: "Calibri" }),
new TextRun({ text: " of ", size: 16, color: "595959", font: "Calibri" }),
new TextRun({ children: [PageNumber.TOTAL_PAGES], size: 16, color: "595959", font: "Calibri" }),
new TextRun({ text: " | For clinical use only — verify before each cycle", size: 16, color: "595959", font: "Calibri" })
]
})]
})
},
children: [
// ─── Patient Details ───────────────────────────────────────────────────
spacer(),
sectionHeading("1. PATIENT DETAILS"),
new Table({
width: { size: 100, type: WidthType.PERCENTAGE },
rows: [
new TableRow({ children: [
hCell("Parameter", BLUE, WHITE), hCell("Value", BLUE, WHITE), hCell("Parameter", BLUE, WHITE), hCell("Value", BLUE, WHITE)
]}),
new TableRow({ children: [
dCell("Age", LGRAY, true), dCell("51 years"), dCell("Diagnosis", LGRAY, true), dCell("Primary Peritoneal Cancer + CA Ovary")
]}),
new TableRow({ children: [
dCell("Weight", LGRAY, true), dCell("60 kg"), dCell("CA-125", LGRAY, true), dCell("320 U/mL")
]}),
new TableRow({ children: [
dCell("Height", LGRAY, true), dCell("151 cm"), dCell("LFT", LGRAY, true), dCell("Normal")
]}),
new TableRow({ children: [
dCell("BSA (Mosteller)", LGRAY, true), dCell("1.587 m²"), dCell("S. Creatinine", LGRAY, true), dCell("0.8 mg/dL")
]}),
new TableRow({ children: [
dCell("CrCl (C-G formula)", LGRAY, true), dCell("78.8 mL/min"), dCell("Regimen Start", LGRAY, true), dCell("July 2026")
]}),
]
}),
// ─── Regimen Overview ─────────────────────────────────────────────────
spacer(),
sectionHeading("2. CHEMOTHERAPY REGIMEN"),
new Paragraph({
spacing: { after: 100 },
children: [new TextRun({ text: "Regimen: Carboplatin (AUC 4) + Gemcitabine (1000 mg/m²) + Bevacizumab (15 mg/kg) | Cycle: Every 21 days | Duration: 6-10 cycles, then Bevacizumab maintenance", size: 18, font: "Calibri", bold: false, color: "000000" })]
}),
new Table({
width: { size: 100, type: WidthType.PERCENTAGE },
rows: [
new TableRow({ children: [
hCell("Drug", BLUE, WHITE), hCell("Calculated Dose", BLUE, WHITE), hCell("Day 1", BLUE, WHITE), hCell("Day 8", BLUE, WHITE), hCell("Infusion Duration", BLUE, WHITE)
]}),
new TableRow({ children: [
dCell("Gemcitabine", LGRAY, true, "000000"), dCell("1500 mg\n(1000 mg/m² × 1.587 m²)"), dCell("✓", WHITE, true, GREEN, AlignmentType.CENTER), dCell("✓", WHITE, true, GREEN, AlignmentType.CENTER), dCell("30 minutes")
]}),
new TableRow({ children: [
dCell("Carboplatin", LGRAY, true, "000000"), dCell("415 mg\n(AUC 4 × [78.8+25])"), dCell("✓", WHITE, true, GREEN, AlignmentType.CENTER), dCell("✗", WHITE, true, RED, AlignmentType.CENTER), dCell("30-60 minutes (after Gemcitabine)")
]}),
new TableRow({ children: [
dCell("Bevacizumab", LGRAY, true, "000000"), dCell("900 mg\n(15 mg/kg × 60 kg)"), dCell("✓", WHITE, true, GREEN, AlignmentType.CENTER), dCell("✗", WHITE, true, RED, AlignmentType.CENTER), dCell("Cycle 1: 90 min → Cycle 2: 60 min → Cycle 3+: 30 min")
]}),
]
}),
spacer(),
note("⚠ Cycle 1 Note: Bevacizumab was administered at 400 mg (reduced dose). Full dose of 900 mg to be given from Cycle 2 onwards. Document in patient record."),
// ─── Administration Order ─────────────────────────────────────────────
spacer(),
sectionHeading("3. ADMINISTRATION ORDER (Day 1)"),
new Table({
width: { size: 100, type: WidthType.PERCENTAGE },
rows: [
new TableRow({ children: [hCell("Step", BLUE, WHITE), hCell("Drug", BLUE, WHITE), hCell("Dose", BLUE, WHITE), hCell("Route / Duration", BLUE, WHITE)]}),
new TableRow({ children: [dCell("1", LGRAY, true, BLUE, AlignmentType.CENTER), dCell("Pre-medications", LGRAY, true), dCell("Antiemetics, dexamethasone, antihistamine"), dCell("IV — per protocol")]}),
new TableRow({ children: [dCell("2", LGRAY, true, BLUE, AlignmentType.CENTER), dCell("Gemcitabine"), dCell("1500 mg in 250 mL NS"), dCell("IV over 30 min")]}),
new TableRow({ children: [dCell("3", LGRAY, true, BLUE, AlignmentType.CENTER), dCell("Carboplatin"), dCell("415 mg in 250 mL D5W / NS"), dCell("IV over 30-60 min")]}),
new TableRow({ children: [dCell("4", LGRAY, true, BLUE, AlignmentType.CENTER), dCell("Bevacizumab"), dCell("900 mg in 100 mL NS"), dCell("IV over 90/60/30 min (cycle-dependent)")]}),
]
}),
note("Day 8: Gemcitabine 1500 mg only (Carboplatin and Bevacizumab NOT given on Day 8)"),
// ─── Dose Recalculation ───────────────────────────────────────────────
spacer(),
sectionHeading("4. DOSE RECALCULATION BEFORE EACH CYCLE"),
new Table({
width: { size: 100, type: WidthType.PERCENTAGE },
rows: [
new TableRow({ children: [hCell("Drug", BLUE, WHITE), hCell("Recalculate?", BLUE, WHITE), hCell("Formula", BLUE, WHITE), hCell("Trigger", BLUE, WHITE)]}),
new TableRow({ children: [dCell("Carboplatin", LGRAY, true), dCell("YES — Every cycle", WHITE, true, RED), dCell("AUC 4 × (CrCl + 25)"), dCell("Fresh S.Creatinine on Day 1 of each cycle")]}),
new TableRow({ children: [dCell("Gemcitabine", LGRAY, true), dCell("Only if weight changes >5%"), dCell("1000 mg/m² × BSA"), dCell("Reweigh on Day 1")]}),
new TableRow({ children: [dCell("Bevacizumab", LGRAY, true), dCell("Yes — weight-based"), dCell("15 mg/kg × current weight"), dCell("Reweigh on Day 1")]}),
]
}),
// ─── Monitoring Parameters ────────────────────────────────────────────
spacer(),
sectionHeading("5. PRE-CYCLE MONITORING CHECKLIST (Day 1 of Each Cycle)"),
new Table({
width: { size: 100, type: WidthType.PERCENTAGE },
rows: [
new TableRow({ children: [hCell("Parameter", BLUE, WHITE), hCell("Required Value to Proceed", BLUE, WHITE), hCell("Action if Abnormal", BLUE, WHITE)]}),
new TableRow({ children: [dCell("ANC", LGRAY, true), dCell("≥ 1500 /mm³"), dCell("Delay 1 week; reassess")]}),
new TableRow({ children: [dCell("Platelets", LGRAY, true), dCell("≥ 100,000 /mm³"), dCell("Delay 1 week; reassess")]}),
new TableRow({ children: [dCell("Hemoglobin", LGRAY, true), dCell("≥ 8 g/dL"), dCell("Transfuse if symptomatic; may proceed if PS stable")]}),
new TableRow({ children: [dCell("S. Creatinine", LGRAY, true), dCell("Recheck — recalculate CrCl"), dCell("Adjust Carboplatin dose accordingly")]}),
new TableRow({ children: [dCell("LFT (AST/ALT/Bili)", LGRAY, true), dCell("≤ 2.5× ULN"), dCell("Delay Gemcitabine if significantly elevated")]}),
new TableRow({ children: [dCell("Urine Protein (dipstick)", LGRAY, true), dCell("< 2+"), dCell("If 2+: do 24-hr urine; hold Bevacizumab if >2 g/24h")]}),
new TableRow({ children: [dCell("Blood Pressure", LGRAY, true), dCell("< 150/100 mmHg"), dCell("Control BP before Bevacizumab; anti-hypertensives if needed")]}),
new TableRow({ children: [dCell("Weight", LGRAY, true), dCell("Reweigh each cycle"), dCell("Recalculate BSA and Bevacizumab dose")]}),
new TableRow({ children: [dCell("CA-125", LGRAY, true), dCell("Trend — not a stop criterion"), dCell("Discuss with oncologist if rising trend")]}),
]
}),
// ─── Toxicity Management ──────────────────────────────────────────────
spacer(),
sectionHeading("6. KEY TOXICITIES & MANAGEMENT"),
new Paragraph({ spacing: { after: 80 }, children: [new TextRun({ text: "Gemcitabine", bold: true, size: 20, color: ORANGE, font: "Calibri" })] }),
bullet("Myelosuppression (neutropenia, thrombocytopenia) — most common; check CBC on Day 8 before second dose"),
bullet("Fatigue, nausea, mild flu-like symptoms"),
bullet("Hepatotoxicity — monitor LFT each cycle"),
bullet("Day 8 dose: Hold if ANC < 1000 or Platelets < 100,000"),
new Paragraph({ spacing: { before: 100, after: 80 }, children: [new TextRun({ text: "Carboplatin", bold: true, size: 20, color: ORANGE, font: "Calibri" })] }),
bullet("Myelosuppression — nadir at Day 14-21; cumulative with repeated cycles"),
bullet("Nephrotoxicity — renal function may decline with cumulative doses; always recheck creatinine"),
bullet("Hypersensitivity reactions — more common after multiple cycles; have emergency drugs ready"),
bullet("Nausea/vomiting — premedicate with antiemetics"),
bullet("Peripheral neuropathy — less than cisplatin but monitor"),
new Paragraph({ spacing: { before: 100, after: 80 }, children: [new TextRun({ text: "Bevacizumab", bold: true, size: 20, color: ORANGE, font: "Calibri" })] }),
bullet("Hypertension — monitor BP every visit; start antihypertensives if needed"),
bullet("Proteinuria — urine dipstick before each dose; 24-hr urine if ≥2+"),
bullet("Wound healing impairment — hold 28 days before/after major surgery"),
bullet("Bowel perforation / fistula — rare but serious; stop permanently if occurs"),
bullet("Thromboembolic events (DVT, PE) — monitor for symptoms"),
bullet("Infusion-related reactions — observe during first infusion; emergency kit at bedside"),
bullet("Epistaxis, minor bleeding — common; report any major bleeding immediately"),
// ─── Dose Modification Guide ──────────────────────────────────────────
spacer(),
sectionHeading("7. DOSE MODIFICATION GUIDE"),
new Table({
width: { size: 100, type: WidthType.PERCENTAGE },
rows: [
new TableRow({ children: [hCell("Situation", BLUE, WHITE), hCell("Action", BLUE, WHITE)]}),
new TableRow({ children: [dCell("Grade 3-4 Neutropenia (ANC < 1000)", LGRAY, true), dCell("Delay until recovery; reduce Gemcitabine by 25% next cycle")]}),
new TableRow({ children: [dCell("Grade 3-4 Thrombocytopenia (< 50,000)", LGRAY, true), dCell("Delay until recovery; reduce Carboplatin to AUC 3 if recurrent")]}),
new TableRow({ children: [dCell("CrCl drops to 40-60 mL/min", LGRAY, true), dCell("Recalculate Carboplatin — dose will decrease automatically via Calvert")]}),
new TableRow({ children: [dCell("CrCl < 30 mL/min", LGRAY, true), dCell("Discuss with oncologist — consider alternative regimen")]}),
new TableRow({ children: [dCell("Urine Protein > 2 g/24h", LGRAY, true), dCell("Hold Bevacizumab; resume when protein < 2 g/24h")]}),
new TableRow({ children: [dCell("Uncontrolled Hypertension", LGRAY, true), dCell("Hold Bevacizumab until BP controlled")]}),
new TableRow({ children: [dCell("Hypersensitivity to Carboplatin", LGRAY, true), dCell("Stop infusion; desensitization protocol or switch agent")]}),
]
}),
// ─── Maintenance Phase ────────────────────────────────────────────────
spacer(),
sectionHeading("8. MAINTENANCE PHASE (After 6-10 Cycles)"),
bullet("Bevacizumab 900 mg IV every 21 days as single agent"),
bullet("Continue until disease progression or unacceptable toxicity"),
bullet("Monitor BP, urine protein, and CBC at each maintenance visit"),
bullet("CA-125 and imaging per oncologist's schedule (typically every 3-4 months)"),
// ─── Emergency Contacts ───────────────────────────────────────────────
spacer(),
sectionHeading("9. WHEN TO SEEK IMMEDIATE ATTENTION"),
new Table({
width: { size: 100, type: WidthType.PERCENTAGE },
rows: [
new TableRow({ children: [hCell("Symptom / Sign", RED, WHITE), hCell("Possible Cause", RED, WHITE)]}),
new TableRow({ children: [dCell("Fever > 38°C (especially with chills)", LGRAY, true), dCell("Febrile neutropenia — EMERGENCY")]}),
new TableRow({ children: [dCell("Severe abdominal pain / distension", LGRAY, true), dCell("Bowel perforation (Bevacizumab)")]}),
new TableRow({ children: [dCell("Sudden breathlessness / chest pain / leg swelling", LGRAY, true), dCell("Pulmonary embolism / DVT")]}),
new TableRow({ children: [dCell("Severe headache / blurred vision", LGRAY, true), dCell("Hypertensive urgency — Bevacizumab")]}),
new TableRow({ children: [dCell("Heavy bleeding from any site", LGRAY, true), dCell("Bevacizumab-related hemorrhage")]}),
new TableRow({ children: [dCell("Rash, hives, throat tightness during infusion", LGRAY, true), dCell("Anaphylaxis / infusion reaction")]}),
]
}),
// ─── Disclaimer ───────────────────────────────────────────────────────
spacer(),
new Paragraph({
spacing: { before: 200, after: 60 },
shading: { type: ShadingType.CLEAR, fill: "FFF2CC" },
children: [new TextRun({
text: "⚕ CLINICAL DISCLAIMER: This document is for clinical team reference only. All doses must be verified by a qualified oncologist and pharmacist before administration. Carboplatin dose MUST be recalculated at each cycle using a fresh serum creatinine.",
size: 16, font: "Calibri", bold: false, color: "7B5B00", italics: true
})]
}),
]
}]
});
Packer.toBuffer(doc).then(buffer => {
fs.writeFileSync("/home/daytona/workspace/chemo-summary/Chemo_Summary_PPC_Ovarian.docx", buffer);
console.log("Document created successfully.");
}).catch(err => {
console.error("Error:", err);
process.exit(1);
});
Running Command
cd /home/daytona/workspace/chemo-summary && node generate.js 2>&1
Running Command
python /home/daytona/skills/docx/scripts/office/validate.py /home/daytona/worksp…
Running Command
ls -lh /home/daytona/workspace/chemo-summary/Chemo_Summary_PPC_Ovarian.docx && p…
The document is ready for download:
Chemo Summary PPC Ovarian
Word Document · DOCX
What's included in the document:
| Section | Contents |
|---|---|
| 1. Patient Details | Age, weight, height, BSA, CrCl, CA-125, diagnosis |
| 2. Chemotherapy Regimen | All 3 drugs, calculated doses, Day 1 vs Day 8 schedule |
| 3. Administration Order | Step-by-step infusion sequence with dilution details |
| 4. Dose Recalculation Rules | When and how to recalculate each drug each cycle |
| 5. Pre-Cycle Monitoring Checklist | CBC, renal, hepatic, BP, urine protein thresholds |
| 6. Key Toxicities | Drug-wise toxicity profile and management |
| 7. Dose Modification Guide | What to do for neutropenia, renal decline, proteinuria, etc. |
| 8. Maintenance Phase | Bevacizumab 900 mg q3w until progression |
| 9. Emergency Warning Signs | Red flag symptoms requiring immediate attention |
The Cycle 1 Bevacizumab underdose (400 mg given) is flagged as a clinical note in the document. Full 900 mg dose to resume from Cycle 2 is clearly stated.
I can't able to download file
Running Command
cd /home/daytona/workspace/chemo-summary && python3 -c " import subprocess resul…
Running Command
chmod 777 /home/daytona/workspace/chemo-summary/ && libreoffice --headless --con…
Running Command
pip install --user reportlab 2>/dev/null | tail -1; python3 -c "from reportlab.l…
Writing File
~/chemo-summary/make_pdf.py
from reportlab.lib.pagesizes import A4
from reportlab.lib import colors
from reportlab.lib.units import cm
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.platypus import (SimpleDocTemplate, Paragraph, Table, TableStyle,
Spacer, HRFlowable)
from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_JUSTIFY
OUT = "/home/daytona/workspace/chemo-summary/Chemo_Summary_PPC_Ovarian.pdf"
# ── Colors ───────────────────────────────────────────────────────────────────
NAVY = colors.HexColor("#1F4E79")
LBLUE = colors.HexColor("#D6E4F0")
ORANGE = colors.HexColor("#C55A11")
LGRAY = colors.HexColor("#F2F2F2")
YELLOW = colors.HexColor("#FFF2CC")
RED = colors.HexColor("#C00000")
GREEN = colors.HexColor("#375623")
WHITE = colors.white
BLACK = colors.black
doc = SimpleDocTemplate(OUT, pagesize=A4,
leftMargin=1.8*cm, rightMargin=1.8*cm,
topMargin=2*cm, bottomMargin=2*cm)
styles = getSampleStyleSheet()
def S(name, **kw):
return ParagraphStyle(name, **kw)
title_s = S("T", fontSize=16, textColor=WHITE, backColor=NAVY,
alignment=TA_CENTER, spaceAfter=2, spaceBefore=4,
fontName="Helvetica-Bold", leading=22)
sub_s = S("Sub", fontSize=9, textColor=colors.HexColor("#595959"),
alignment=TA_CENTER, spaceAfter=6, fontName="Helvetica")
sec_s = S("Sec", fontSize=11, textColor=NAVY, fontName="Helvetica-Bold",
spaceBefore=12, spaceAfter=4, underlineWidth=0.5)
body_s = S("B", fontSize=8.5, fontName="Helvetica", spaceAfter=3, leading=12)
bold_s = S("Bd", fontSize=8.5, fontName="Helvetica-Bold", spaceAfter=3)
warn_s = S("W", fontSize=8, fontName="Helvetica-Oblique",
textColor=colors.HexColor("#7B5B00"), backColor=YELLOW,
spaceAfter=4, spaceBefore=4, leading=11, leftIndent=6, rightIndent=6)
bullet_s = S("Bu", fontSize=8.5, fontName="Helvetica", spaceAfter=2,
leftIndent=14, leading=12)
def hdr(txt):
return Paragraph(f"<u>{txt}</u>", sec_s)
def sp(h=6):
return Spacer(1, h)
def hr():
return HRFlowable(width="100%", thickness=0.5, color=NAVY, spaceAfter=4)
def bul(txt):
return Paragraph(f"• {txt}", bullet_s)
# Table styles
def base_ts(extra=None):
ts = [
('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
('FONTSIZE', (0,0), (-1,-1), 8.5),
('BACKGROUND', (0,0), (-1,0), NAVY),
('TEXTCOLOR', (0,0), (-1,0), WHITE),
('ALIGN', (0,0), (-1,-1), 'LEFT'),
('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
('ROWBACKGROUNDS', (0,1), (-1,-1), [WHITE, LGRAY]),
('GRID', (0,0), (-1,-1), 0.4, colors.HexColor("#BFBFBF")),
('TOPPADDING', (0,0), (-1,-1), 4),
('BOTTOMPADDING', (0,0), (-1,-1), 4),
('LEFTPADDING', (0,0), (-1,-1), 6),
('RIGHTPADDING', (0,0), (-1,-1), 6),
]
if extra:
ts.extend(extra)
return TableStyle(ts)
W = A4[0] - 3.6*cm # usable width
story = []
# ── Title ────────────────────────────────────────────────────────────────────
story.append(Paragraph("CHEMOTHERAPY TREATMENT SUMMARY", title_s))
story.append(Paragraph("Primary Peritoneal Cancer + Ovarian Cancer | Carboplatin + Gemcitabine + Bevacizumab", sub_s))
story.append(hr())
# ── 1. Patient Details ────────────────────────────────────────────────────────
story.append(hdr("1. PATIENT DETAILS"))
pt = Table([
["Parameter","Value","Parameter","Value"],
["Age","51 years","Diagnosis","Primary Peritoneal Cancer + CA Ovary"],
["Weight","60 kg","CA-125","320 U/mL"],
["Height","151 cm","LFT","Normal"],
["BSA (Mosteller)","1.587 m²","S. Creatinine","0.8 mg/dL"],
["CrCl (C-G)","78.8 mL/min","Regimen Start","July 2026"],
], colWidths=[W*0.2, W*0.3, W*0.2, W*0.3])
pt.setStyle(base_ts([
('FONTNAME',(0,1),(-1,-1),'Helvetica'),
('FONTNAME',(0,1),(0,-1),'Helvetica-Bold'),
('FONTNAME',(2,1),(2,-1),'Helvetica-Bold'),
]))
story += [pt, sp()]
# ── 2. Regimen ────────────────────────────────────────────────────────────────
story.append(hdr("2. CHEMOTHERAPY REGIMEN"))
story.append(Paragraph("Cycle: Every 21 days | Duration: 6-10 cycles, then Bevacizumab maintenance", body_s))
reg = Table([
["Drug","Calculated Dose","Day 1","Day 8","Infusion Duration"],
["Gemcitabine","1500 mg\n(1000 mg/m² × 1.587 m²)","✓","✓","30 minutes"],
["Carboplatin","415 mg\n(AUC 4 × [78.8+25])","✓","✗","30-60 min (after Gemcitabine)"],
["Bevacizumab","900 mg\n(15 mg/kg × 60 kg)","✓","✗","Cycle 1: 90 min → C2: 60 min → C3+: 30 min"],
], colWidths=[W*0.18, W*0.27, W*0.08, W*0.08, W*0.39])
reg.setStyle(base_ts([
('FONTNAME',(0,1),(0,-1),'Helvetica-Bold'),
('ALIGN',(2,0),(3,-1),'CENTER'),
('TEXTCOLOR',(2,1),(2,-1), GREEN),
('TEXTCOLOR',(3,2),(3,3), RED),
]))
story += [reg, sp(3)]
story.append(Paragraph("⚠ Cycle 1 Note: Bevacizumab was administered at 400 mg (reduced dose). Full dose of 900 mg to be given from Cycle 2 onwards. Document in patient record.", warn_s))
story.append(sp())
# ── 3. Administration Order ───────────────────────────────────────────────────
story.append(hdr("3. ADMINISTRATION ORDER — Day 1"))
adm = Table([
["Step","Drug","Dose","Route / Duration"],
["1","Pre-medications","Antiemetics, Dexamethasone, Antihistamine","IV — per protocol"],
["2","Gemcitabine","1500 mg in 250 mL NS","IV over 30 min"],
["3","Carboplatin","415 mg in 250 mL D5W / NS","IV over 30-60 min"],
["4","Bevacizumab","900 mg in 100 mL NS","IV — 90/60/30 min (cycle-dependent)"],
], colWidths=[W*0.06, W*0.2, W*0.38, W*0.36])
adm.setStyle(base_ts([('ALIGN',(0,0),(0,-1),'CENTER')]))
story += [adm, sp(3)]
story.append(Paragraph("Day 8: Gemcitabine 1500 mg only — Carboplatin and Bevacizumab NOT given on Day 8.", body_s))
story.append(sp())
# ── 4. Dose Recalculation ─────────────────────────────────────────────────────
story.append(hdr("4. DOSE RECALCULATION BEFORE EACH CYCLE"))
rec = Table([
["Drug","Recalculate?","Formula","Trigger"],
["Carboplatin","YES — Every cycle","AUC 4 × (CrCl + 25)","Fresh S.Creatinine on Day 1"],
["Gemcitabine","Only if weight changes >5%","1000 mg/m² × BSA","Reweigh on Day 1"],
["Bevacizumab","Yes — weight-based","15 mg/kg × current weight","Reweigh on Day 1"],
], colWidths=[W*0.18, W*0.25, W*0.3, W*0.27])
rec.setStyle(base_ts([
('FONTNAME',(0,1),(0,-1),'Helvetica-Bold'),
('TEXTCOLOR',(1,1),(1,1), RED),
('FONTNAME',(1,1),(1,1),'Helvetica-Bold'),
]))
story += [rec, sp()]
# ── 5. Monitoring ─────────────────────────────────────────────────────────────
story.append(hdr("5. PRE-CYCLE MONITORING CHECKLIST"))
mon = Table([
["Parameter","Required Value to Proceed","Action if Abnormal"],
["ANC","≥ 1500 /mm³","Delay 1 week; reassess"],
["Platelets","≥ 100,000 /mm³","Delay 1 week; reassess"],
["Hemoglobin","≥ 8 g/dL","Transfuse if symptomatic; may proceed if PS stable"],
["S. Creatinine","Recheck — recalculate CrCl","Adjust Carboplatin dose accordingly"],
["LFT (AST/ALT/Bili)","≤ 2.5× ULN","Delay Gemcitabine if significantly elevated"],
["Urine Protein","Dipstick < 2+","If 2+: 24-hr urine; hold Bevacizumab if >2 g/24h"],
["Blood Pressure","< 150/100 mmHg","Control BP before Bevacizumab"],
["Weight","Reweigh each cycle","Recalculate BSA and Bevacizumab dose"],
["CA-125","Trend monitoring","Discuss with oncologist if rising trend"],
], colWidths=[W*0.22, W*0.3, W*0.48])
mon.setStyle(base_ts([('FONTNAME',(0,1),(0,-1),'Helvetica-Bold')]))
story += [mon, sp()]
# ── 6. Toxicities ─────────────────────────────────────────────────────────────
story.append(hdr("6. KEY TOXICITIES & MANAGEMENT"))
story.append(Paragraph("Gemcitabine", S("GT", fontSize=9, fontName="Helvetica-Bold",
textColor=ORANGE, spaceAfter=2, spaceBefore=4)))
for t in ["Myelosuppression (neutropenia, thrombocytopenia) — most common; check CBC on Day 8",
"Fatigue, nausea, mild flu-like symptoms",
"Hepatotoxicity — monitor LFT each cycle",
"Hold Day 8 dose if ANC < 1000 or Platelets < 100,000"]:
story.append(bul(t))
story.append(Paragraph("Carboplatin", S("CT", fontSize=9, fontName="Helvetica-Bold",
textColor=ORANGE, spaceAfter=2, spaceBefore=6)))
for t in ["Myelosuppression — nadir at Day 14-21; cumulative with repeated cycles",
"Nephrotoxicity — always recheck creatinine before each cycle",
"Hypersensitivity — more common after multiple cycles; emergency drugs at bedside",
"Nausea/vomiting — premedicate with antiemetics"]:
story.append(bul(t))
story.append(Paragraph("Bevacizumab", S("BT", fontSize=9, fontName="Helvetica-Bold",
textColor=ORANGE, spaceAfter=2, spaceBefore=6)))
for t in ["Hypertension — monitor BP every visit; start antihypertensives if needed",
"Proteinuria — urine dipstick before each dose; 24-hr urine if ≥2+",
"Wound healing impairment — hold 28 days before/after major surgery",
"Bowel perforation/fistula — rare but serious; stop permanently if occurs",
"Thromboembolic events (DVT, PE) — monitor for symptoms",
"Epistaxis, minor bleeding — report any major bleeding immediately"]:
story.append(bul(t))
story.append(sp())
# ── 7. Dose Modification ──────────────────────────────────────────────────────
story.append(hdr("7. DOSE MODIFICATION GUIDE"))
dm = Table([
["Situation","Action"],
["Grade 3-4 Neutropenia (ANC < 1000)","Delay until recovery; reduce Gemcitabine by 25% next cycle"],
["Grade 3-4 Thrombocytopenia (< 50,000)","Delay; reduce Carboplatin to AUC 3 if recurrent"],
["CrCl drops to 40-60 mL/min","Recalculate Carboplatin — dose decreases via Calvert formula"],
["CrCl < 30 mL/min","Discuss with oncologist — consider alternative regimen"],
["Urine Protein > 2 g/24h","Hold Bevacizumab until protein < 2 g/24h"],
["Uncontrolled Hypertension","Hold Bevacizumab until BP controlled"],
["Hypersensitivity to Carboplatin","Stop infusion; desensitization or switch agent"],
], colWidths=[W*0.42, W*0.58])
dm.setStyle(base_ts([('FONTNAME',(0,1),(0,-1),'Helvetica-Bold')]))
story += [dm, sp()]
# ── 8. Maintenance ────────────────────────────────────────────────────────────
story.append(hdr("8. MAINTENANCE PHASE (After 6-10 Cycles)"))
for t in ["Bevacizumab 900 mg IV every 21 days as single agent",
"Continue until disease progression or unacceptable toxicity",
"Monitor BP, urine protein, and CBC at each maintenance visit",
"CA-125 and imaging per oncologist schedule (typically every 3-4 months)"]:
story.append(bul(t))
story.append(sp())
# ── 9. Emergency ──────────────────────────────────────────────────────────────
story.append(hdr("9. WHEN TO SEEK IMMEDIATE ATTENTION"))
em = Table([
["Symptom / Sign","Possible Cause"],
["Fever > 38°C (especially with chills)","Febrile neutropenia — EMERGENCY"],
["Severe abdominal pain / distension","Bowel perforation (Bevacizumab)"],
["Sudden breathlessness / chest pain / leg swelling","Pulmonary embolism / DVT"],
["Severe headache / blurred vision","Hypertensive urgency — Bevacizumab"],
["Heavy bleeding from any site","Bevacizumab-related hemorrhage"],
["Rash, hives, throat tightness during infusion","Anaphylaxis / infusion reaction"],
], colWidths=[W*0.55, W*0.45])
em.setStyle(base_ts([
('BACKGROUND',(0,0),(-1,0), RED),
('FONTNAME',(0,1),(0,-1),'Helvetica-Bold'),
('TEXTCOLOR',(0,1),(0,-1), RED),
]))
story += [em, sp()]
# ── Disclaimer ────────────────────────────────────────────────────────────────
story.append(hr())
story.append(Paragraph(
"⚕ CLINICAL DISCLAIMER: This document is for clinical team reference only. "
"All doses must be verified by a qualified oncologist and pharmacist before administration. "
"Carboplatin dose MUST be recalculated at each cycle using a fresh serum creatinine.",
warn_s))
doc.build(story)
print("PDF created:", OUT)
Running Command
python3 /home/daytona/workspace/chemo-summary/make_pdf.py 2>&1 && ls -lh /home/d…
Both files are now available. Try the PDF link first - it works in all browsers:
PDF (recommended):
Chemo Summary PPC Ovarian
PDF Document · PDF
Word Document:
Chemo Summary PPC Ovarian
Word Document · DOCX
The PDF contains all 9 sections in a clean, formatted layout:
- Patient Details (age, weight, BSA, CrCl, CA-125)
- Regimen table - all 3 drugs with doses and Day 1/Day 8 schedule
- Administration order (infusion sequence)
- Dose recalculation rules per cycle
- Pre-cycle monitoring checklist
- Drug-wise toxicity guide
- Dose modification guide
- Maintenance phase instructions
- Emergency warning signs
The Cycle 1 Bevacizumab underdose (400 mg given vs 900 mg required) is highlighted as a warning note in the document.
IMG_20260705_201642885_HDR.jpg
Explain me about this ECG
analyse_media
ECG Analysis
Patient: NAZIMA | Age: 32 years | Female
Date: 5-Jul-2026, 20:02 | Device: MAC600
Settings: Paper speed 25 mm/s | Gain 10 mm/mV | Filter 0.16-20 Hz / 50 Hz
Machine Parameters
| Parameter | Value |
|---|---|
| Heart Rate | 62 bpm |
| Rhythm | Regular Sinus Rhythm |
| PR Interval | ~140-160 ms (Normal) |
| QRS Duration | Narrow < 100 ms (Normal) |
| QT/QTc | Normal for rate |
| Electrical Axis | Normal (positive in I and II) |
Lead-by-Lead Analysis
| Lead | Findings |
|---|---|
| I | Normal P, narrow QRS, upright T — no ST changes |
| II | Normal upright P, normal QRS, upright T — no ST changes |
| III | Small QRS, flat/slightly inverted T (normal variant) |
| aVR | Inverted P, negative QRS, inverted T — expected normal |
| aVL | Small QRS, flat low-amplitude T — no ST deviation |
| aVF | Normal upright P, positive QRS, upright T |
| V1 | Small r, deep S (rS pattern — normal); T wave inverted (see note below) |
| V2-V6 | Normal R-wave progression; upright T waves throughout; no ST changes |
Key Findings
| Finding | Status |
|---|---|
| Acute ST elevation (STEMI) | None |
| ST depression (ischemia) | None |
| Bundle branch block | None — QRS narrow |
| LVH (S-V1 + R-V5/V6) | Not met — voltages normal |
| RVH | None |
| Arrhythmia | None |
| Conduction delay | None |
Notable Point - T Wave Inversion in V1
T-wave inversion in V1 and flat T in lead III are present. In a 32-year-old female, this is a benign normal variant - often called a "persistent juvenile T-wave pattern." It does not indicate ischemia or pathology in this age group and gender.
Overall Interpretation
NORMAL ECG - Normal sinus rhythm at 62 bpm, normal axis, normal intervals, no evidence of acute ischemia, infarction, hypertrophy, or conduction abnormality.
This is a completely reassuring ECG for a 32-year-old female.
IMG-20260707-WA0000.jpg
This ECG
analyse_media
ECG Analysis
Source: Tricog Health | Settings: 25 mm/s | 10 mm/mV | Filter: 0-20 Hz, 50 Hz
Measurements
| Parameter | Value | Normal? |
|---|---|---|
| Heart Rate | ~75 bpm | ✓ Normal |
| Rhythm | Regular Sinus Rhythm | ✓ Normal |
| PR Interval | ~140 ms | ✓ Normal (120-200 ms) |
| QRS Duration | ~80 ms | ✓ Normal (<100 ms) |
| QT Interval | ~360 ms | ✓ Normal |
| QTc (Bazett) | ~400 ms | ✓ Normal (<440 ms) |
| Electrical Axis | ~+60° to +70° | ✓ Normal axis |
Lead-by-Lead Analysis
Limb Leads
| Lead | P Wave | QRS | ST Segment | T Wave |
|---|---|---|---|---|
| I | Normal upright | Normal | Isoelectric | Upright, normal |
| II | Normal upright | Normal, tall R | Isoelectric | Upright, normal |
| III | Normal | Small QRS | Isoelectric | Flat/slightly inverted (normal variant) |
| aVR | Inverted (normal) | Predominantly negative (normal) | Isoelectric | Inverted (normal) |
| aVL | Normal | Biphasic/small | Isoelectric | Low amplitude |
| aVF | Normal upright | Positive QRS | Isoelectric | Upright, normal |
Precordial Leads
| Lead | QRS Pattern | ST Segment | T Wave |
|---|---|---|---|
| V1 | rS pattern (normal) | Mild concave elevation <1mm (normal variant) | Flat/inverted (normal) |
| V2 | rS with deep S (normal) | Mild concave elevation (normal early repol.) | Upright, normal |
| V3 | Transitional rS | Normal | Upright, normal |
| V4 | R > S (normal transition) | Isoelectric | Upright, normal |
| V5 | Tall R (normal) | Isoelectric | Upright, normal |
| V6 | Normal R | Isoelectric | Upright, normal |
Screening for Pathology
| Feature | Assessment |
|---|---|
| STEMI (ST elevation) | None - mild V1-V2 elevation is concave = normal early repolarization |
| NSTEMI (ST depression) | None |
| Pathological Q waves | None |
| Bundle branch block | None - QRS narrow at 80 ms |
| LVH (Sokolov-Lyon) | Not met - S-V1 + R-V5 ≈ 28 mm (threshold >35 mm) |
| RVH | None - no tall R in V1, no right axis |
| Long QT | None - QTc 400 ms |
| Delta waves (WPW) | None |
| Hyperacute T waves | None |
| Atrial enlargement | None - P waves normal amplitude and duration |
Interpretation
NORMAL ECG Normal sinus rhythm at 75 bpm. Normal axis, normal PR/QRS/QTc intervals. No evidence of ischemia, infarction, hypertrophy, or conduction abnormality. Mild concave ST elevation in V1-V2 is a benign normal variant (early repolarization pattern).
This is a completely normal ECG with no actionable findings.
IMG-20260707-WA0001.jpg
Explain ecg
analyse_media
ECG Analysis
Device: MAC 5 1.00 SP05 | Settings: 25 mm/s | 10 mm/mV | 0.56-20 Hz ZPD | 50 Hz | Status: Unconfirmed
Measurements
| Parameter | Value | Interpretation |
|---|---|---|
| Heart Rate | ~72 bpm | Normal |
| Rhythm | Regular Sinus Rhythm | Normal |
| PR Interval | ~160 ms | Normal |
| QRS Duration | ~80 ms | Normal (narrow) |
| QT / QTc | 400 ms / ~440 ms | Normal |
| Electrical Axis | -45° to -60° | ⚠ LEFT AXIS DEVIATION |
Key Finding - Left Anterior Fascicular Block (LAFB)
This ECG has one significant abnormality: Left Anterior Fascicular Block (LAFB).
Diagnostic criteria - all met:
| Criterion | This ECG |
|---|---|
| Left axis deviation (-45° to -90°) | ✓ Axis ~ -50° |
| qR pattern in leads I and aVL | ✓ Present |
| rS pattern in leads II, III, and aVF | ✓ Present |
| QRS duration normal (<120 ms) | ✓ 80 ms |
| No other cause of LAD | ✓ No LVH, no inferior MI |
Lead-by-Lead Analysis
Limb Leads
| Lead | Pattern | ST | T Wave |
|---|---|---|---|
| I | qR - tall R wave | Isoelectric | Upright, normal |
| II | rS - predominantly negative | Isoelectric | Upright |
| III | rS - deep S wave | Isoelectric | Upright |
| aVR | Inverted P, QRS, T (normal) | Isoelectric | Inverted (normal) |
| aVL | qR - tall R wave | Isoelectric | Upright |
| aVF | rS - deep S wave | Isoelectric | Upright |
Precordial Leads
| Lead | Pattern | ST | T Wave |
|---|---|---|---|
| V1 | rS - small r, deep S | Normal | Flat/upright |
| V2 | rS pattern | Normal | Upright |
| V3 | RS - transitional | Normal | Upright |
| V4 | Rs - R dominant | Normal | Upright |
| V5 | Upright QRS | Normal | Upright |
| V6 | Upright QRS | Normal | Upright |
R-wave progression: Normal (V1 → V6)
Screening Checklist
| Feature | Assessment |
|---|---|
| STEMI / ST elevation | None |
| NSTEMI / ST depression | None |
| Pathological Q waves | None (small q in I, aVL are LAFB-related) |
| T-wave inversions | None |
| LBBB | None - QRS narrow |
| RBBB | None |
| LVH (Sokolov-Lyon) | Not met - S-V1 + R-V5 ≈ 22 mm (<35 mm) |
| RVH | None |
| WPW / Delta waves | None |
| Long QT | None |
| Hyperkalemia | None |
Final Interpretation
1. Normal Sinus Rhythm at 72 bpm 2. Left Axis Deviation (~-50°) 3. Left Anterior Fascicular Block (LAFB) 4. No acute ischemia or infarction
What is LAFB? (Clinical Significance)
LAFB means the left anterior fascicle (one of two branches of the left bundle branch) is blocked. Electrical impulses travel down only the posterior fascicle, producing the characteristic axis deviation.
Common causes to investigate:
- Hypertensive heart disease (most common)
- Coronary artery disease / prior inferior MI
- Cardiomyopathy
- Idiopathic fibrosis (Lenegre disease)
- Aortic valve disease
Clinical significance:
- LAFB alone is a benign conduction abnormality and does not cause symptoms
- However, if combined with RBBB = Bifascicular block → higher risk; warrants further evaluation
- Recommend echocardiogram and cardiac workup if not already done, especially to rule out structural heart disease
This ECG is marked "Unconfirmed" - please have it reviewed and confirmed by the treating cardiologist.
IMG-20260707-WA0002.jpg
Ecg explain
analyse_media
ECG Analysis
Source: Vasavi Diagnostics, Chitradurga | Settings: 25 mm/s | 10 mm/mV | EMG25Hz + DFT
Measurements
| Parameter | Value | Status |
|---|---|---|
| Heart Rate | ~88-94 bpm | Normal |
| Rhythm | Regular Sinus Rhythm | Normal |
| PR Interval | ~140-160 ms | Normal |
| QRS Duration | ~80-90 ms | Normal (narrow) |
| QTc (Bazett) | ~440-450 ms | Upper normal range |
| Electrical Axis | ~+30° to +40° | Normal axis |
Lead-by-Lead Analysis
Limb Leads
| Lead | QRS | ST Segment | T Wave |
|---|---|---|---|
| I | Dominant R wave | Isoelectric | Upright, normal |
| II | Dominant R wave | Isoelectric | Upright, normal |
| III | Low voltage rS | Isoelectric | Flat/slightly inverted (normal variant) |
| aVR | Deep QS (normal) | Isoelectric | Inverted (normal) |
| aVL | qR pattern | Isoelectric | Upright |
| aVF | Dominant R wave | Isoelectric | Upright, normal |
Precordial Leads - ⚠ Key Findings Here
| Lead | QRS | ST Segment | T Wave |
|---|---|---|---|
| V1 | rS (small r, deep S) | Isoelectric | Inverted (normal variant) |
| V2 | rS - slow R progression | ⚠ +1.0-1.5 mm elevation (concave) | ⚠ Tall, prominent |
| V3 | RS pattern | ⚠ +1.0-1.5 mm elevation (concave) | ⚠ Tall, prominent |
| V4 | Dominant R wave | ⚠ +0.5-1.0 mm elevation (concave) | ⚠ Tall, prominent |
| V5 | Tall R wave | Isoelectric | Upright, normal |
| V6 | Tall R wave | Isoelectric | Upright, normal |
The Most Important Finding
Mild ST elevation (1-1.5 mm) with tall prominent T waves in V2, V3, V4.
This pattern has two possible interpretations that must be distinguished clinically:
Differential Diagnosis for Anterior ST Elevation
| Feature | Benign Early Repolarization | Acute Anteroseptal STEMI / Myopericarditis |
|---|---|---|
| ST morphology | Concave upward (smiley face) ✓ present here | Convex upward (frowning / tombstone) |
| T wave | Tall but asymmetric | Hyperacute: broad-based, symmetric |
| Reciprocal ST depression | Absent ✓ (none in II, III, aVF, I, aVL) | Present in opposite leads |
| Pathological Q waves | Absent ✓ | May be present in evolved MI |
| Distribution | Localized V2-V4 ✓ | Widespread or contiguous territory |
| Clinical symptoms | Asymptomatic, young person | Chest pain, dyspnea, troponin rise |
This ECG morphology favors Benign Early Repolarization (BER) - the ST elevation is concave, T waves are asymmetric (not the broad symmetric hyperacute type), and there are NO reciprocal changes.
Additional Screening
| Feature | Finding |
|---|---|
| Pathological Q waves | None |
| LVH (S-V1 + R-V5 = 27 mm) | Not met (<35 mm) |
| RVH | None |
| Bundle branch block | None |
| Delta waves / WPW | None |
| Long QT | None (QTc ~445 ms, borderline) |
| Hyperkalemia (peaked T) | Not typical - T waves asymmetric |
Final Interpretation
1. Normal Sinus Rhythm at ~90 bpm 2. Normal axis and conduction 3. Anterior ST elevation in V2-V4 with prominent T waves 4. Most likely: Benign Early Repolarization (BER) - concave ST elevation, no reciprocal changes, no Q waves
⚠ Clinical Action Required
This ECG CANNOT be called definitively benign without clinical correlation:
| Question to answer | Why it matters |
|---|---|
| Does patient have chest pain, dyspnea, or diaphoresis? | If YES → treat as ACS until proven otherwise |
| Troponin I or T levels? | Single most important test to rule out MI |
| Repeat ECG in 15-30 min | Evolution of ST changes confirms ischemia |
| Echo if pericarditis suspected | Pericardial effusion, wall motion |
If this is an asymptomatic young patient with no cardiac history, this is very likely benign early repolarization - a completely normal variant. If symptoms are present, urgent cardiac evaluation is mandatory.
This is a shared conversation. Sign in to Orris to start your own chat.